Journal: Immunity

Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

doi: 10.1016/j.immuni.2025.02.013

Figure Lengend Snippet: Figure 3. TAC stimulates splenic PlGF secretion to induce cardiac RM proliferation and counteract HF (A and B) Serial LV echocardiography in basal condition and 1–2–4–8 weeks after TAC in Cx3cr1/ and WT mice. EF (A) and RWT (B) are shown. n = 4 WT TAC; n = 5 Cx3cr1/ TAC. Data as mean ± SEM and analyzed by two-way ANOVA and Sidak post hoc. ***p < 0.001.

Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

Techniques:

Journal: Immunity

Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

doi: 10.1016/j.immuni.2025.02.013

Figure Lengend Snippet: Figure 4. Splenic-derived PlGF promotes the expansion of RMs and hinders HF (A and B) Immunofluorescence (A) and quantification (B) of PlGF in the splenic marginal zone delimited by ERTR7+ fibroblast reticular cells in sham or TAC mice subjected to CGX or control (scale bar, 50 mm). n = 6 sham; n = 5 TAC; n = 5 TAC CGX. Data as mean ± SEM and analyzed by one-way ANOVA and Tukey post hoc. *p < 0.05. (legend continued on next page)

Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

Techniques: Derivative Assay, Control

Journal: Immunity

Article Title: A heart-brain-spleen axis controls cardiac remodeling to hypertensive stress.

doi: 10.1016/j.immuni.2025.02.013

Figure Lengend Snippet: Figure 6. PlGF-NRP1 mediates adaptive functions of macrophages during pressure overload (A and B) Flow cytometry (A) and quantification (B) of NRP1 expression in cardiac Ly6CloTimd4Lyve-1+ RMs after TAC. n = 6 sham; n = 7 TAC. Data as mean ± SEM and analyzed by unpaired t test. ***p < 0.001.

Article Snippet: In vivo administration of recombinant PlGF Mice subjected to splenectomy have been treated by intraperitoneal injection of 1,5 mg/Kg body weight of recombinant PlGF (rPlGF) (R&D Systems) and with NaCl 0.9% as vehicle control as previously described.14 Follow up analysis of cardiac remodeling has been performed by echocardiography.

Techniques: Flow Cytometry, Expressing

Journal: Diabetes Therapy

Article Title: Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection

doi: 10.1007/s13300-018-0527-9

Figure Lengend Snippet: Before and after the patients received the intravitreal conbercept treatment and underwent vitrectomy. a Schematic flow diagram of the process in this work. b Concentrations of VEGF and PlGF in the aqueous and vitreous humor pre- and post-intravitreal conbercept injection. c Correlation between the concentrations of VEGF and PlGF in the aqueous and vitreous humor. ** p < 0.01

Article Snippet: ELISA analysis was performed using Human VEGF ELISA kit and Human PlGF ELISA kit (Boster Biological Technology, Wuhan, China) according to the manufacturer’s instructions.

Techniques: Injection